MDT vs BSX vs EW Stock Comparison

Medtronic, Boston Scientific and Edwards Lifesciences Prices as of Nov 13, 2026 Peers: Industry group
MDT Medtronic plc
$102.86 +9.2% 1M +7.0% 1Y
Market cap
$132.09B
P/E
15.1x
Revenue (TTM)
$37.10B
Div. yield
0.03%
Medical Devices Healthcare
4 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$63.94B
P/E
18.3x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
2 wins
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$61.62B
P/E
60.7x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
5 wins

Head to Head

11 decided of 12

Edwards Lifesciences leads on 5 of the 12 questions below (Edwards Lifesciences 5, Medtronic 4, Boston Scientific 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMDTBSXEWLeader
Larger companyMarket capitalisation $132.09B $63.94B $61.62B MDT
Cheaper on earningsLower P/E, profitable companies only 15.1x 18.3x 60.7x MDT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.5x 14.5x 37.6x BSX
Faster revenue growthRevenue growth, trailing twelve months +12.8% +8.9% +13.4% EW
More profitableNet margin, trailing twelve months 23.6% 16.6% 15.2% MDT
Better return on capitalReturn on invested capital 11.7% 9.9% 8.7% MDT
Less leveragedLower net debt / EBITDA 1.2x 2.1x -2.5x EW
Higher dividend yieldTrailing dividend yield 0.03% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.0% -57.8% +24.5% EW
Better 5-year returnAnnualised price return, 5 years -2.9%/yr +1.1%/yr -1.6%/yr BSX
Less volatileAnnualised volatility, 1 year 25.6% 41.5% 25.5% EW
Higher overall scoreMean of the five percentile scores vs peers 63/100 68/100 77/100 EW

Percentile Scorecard

MDTBSXEW

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMDTBSXEW
Valuation 87 #32 of 243 87 #33 of 243 61 #96 of 243
Growth 35 #149 of 228 68 #73 of 228 57 #99 of 228
Profitability 98 #6 of 222 91 #20 of 222 96 #10 of 222
Financial Health 50 #124 of 248 43 #142 of 248 87 #34 of 248
Shareholder Returns 43 #90 of 158 48 #82 of 158 84 #26 of 158
Overall 63 68 77
  • MDT ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics
  • EW ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMDTBSXEWSPY
1 month +9.2%+3.1%+24.0% -2.0%
3 months +12.7%-14.5%+17.0% -2.8%
6 months +35.1%-15.8%+31.7% +2.0%
Year to date +7.1%-53.5%+25.7% +10.6%
1 year +7.0%-57.8%+24.5% +12.2%
3 years +41.7%-17.9%+62.9% +68.1%
3 years, per year +12.3%-6.4%+17.7% +18.9%
5 years -13.8%+5.4%-7.6% +61.4%
5 years, per year -2.9%+1.1%-1.6% +10.1%
10 years +25.3%+106.2%+253.3% +248.5%
10 years, per year +2.3%+7.5%+13.5% +13.3%

Risk

MeasureMDTBSXEWSPY
Volatility, 1Y 25.6%41.5%25.5% 13.6%
Downside volatility, 1Y 22.3%47.7%24.7% 13.9%
Beta vs S&P 500, 1Y 0.140.260.58 1.00
Return / volatility, 1Y 0.27-1.390.96 0.90
Max drawdown, 5Y -41.2%-61.6%-54.3% -25.4%
From 52-week high -2.4%-57.8%0.0% -3.2%
52-week high $105.35$104.98$107.18 $779.14
52-week low $73.75$41.57$75.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMDTBSXEW
P/E now vs peer median 15.0xmedian 26.5x 18.3xmedian 26.5x 60.9xmedian 26.5x
P/S now vs peer median 3.5xmedian 2.7x 3.1xmedian 2.7x 9.2xmedian 2.7x
EV/EBITDA now vs peer median 9.2xmedian 18.4x 14.1xmedian 18.4x 35.8xmedian 18.4x
P/FCF now vs peer median 10.3xmedian 25.4x 19.3xmedian 25.4x 43.3xmedian 25.4x
P/B now vs peer median 2.6xmedian 2.5x 2.5xmedian 2.5x 5.6xmedian 2.5x
PEG now vs peer median 1.85median 0.98 0.42median 0.98 -6.65median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMDTBSXEW
Revenue $37.10B $21.07B $6.67B
Gross profit $24.23B $14.57B $5.21B
Operating income $11.28B $3.93B $1.44B
Net income $8.81B $3.49B $1.02B
Free cash flow $12.74B $3.33B $1.42B
R&D $4.93B $2.16B $1.09B
EPS (diluted) $6.81 $2.41 $1.76
Cash & equivalents $1.69B $609.00M $3.11B
Total debt $28.15B $11.95B $598.80M
Shares (diluted) 1.29B 1.45B 577.60M
Enterprise value $97.60B $59.37B $44.83B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMDTBSXEW
P/E 15.0x 18.3x 60.9x
P/FCF 10.3x 19.3x 43.3x
P/Operating cash flow 10.7x 15.2x 35.9x
P/S 3.5x 3.1x 9.2x
P/B 2.6x 2.5x 5.6x
P/Tangible book 3.2x 3.4x 6.3x
EV/EBITDA 9.2x 14.1x 35.8x
EV/EBIT 13.4x 19.2x 40.0x
EV/Revenue 4.1x 3.6x 8.6x
EV/FCF 11.9x 22.7x 40.5x
EV/Operating cash flow 12.2x 17.9x 33.6x
PEG (3Y EPS CAGR) 1.85 0.42 -6.65

Growth

14 metrics
MetricMDTBSXEW
Revenue growth (1Y) 12.8% 8.9% 13.4%
Revenue CAGR (3Y) 6.7% 15.3% 16.9%
Gross profit growth (1Y) 13.1% 9.8% 13.2%
Gross profit CAGR (3Y) 6.0% 15.1% 13.7%
Operating income growth (1Y) 19.2% 13.5% 1.1%
Operating income CAGR (3Y) 5.7% 22.1% 5.8%
Net income growth (1Y) -17.8% 25.5% -25.2%
Net income CAGR (3Y) -4.4% 41.7% -10.6%
EPS growth (1Y) 24.7% 29.2% -24.5%
EPS CAGR (3Y) 8.1% 44.0% -9.2%
Operating cash flow growth (1Y) -22.3% -8.5% 68.9%
Operating cash flow CAGR (3Y) -6.7% 21.6% 18.1%
Free cash flow growth (1Y) 27.6% -12.9% 77.1%
Free cash flow CAGR (3Y) 6.7% 25.2% 20.8%

Profitability

14 metrics
MetricMDTBSXEW
Gross margin 65.3% 69.1% 78.0%
EBITDA margin 44.0% 25.5% 24.2%
Operating margin 30.4% 18.7% 21.6%
Pretax margin 29.2% 17.3% 21.5%
Net margin 23.6% 16.6% 15.2%
FCF margin 34.3% 15.8% 21.3%
Operating cash flow margin 33.2% 20.1% 25.7%
Return on equity 17.5% 13.7% 9.4%
Return on assets 9.5% 7.7% 7.2%
Return on invested capital 11.7% 9.9% 8.7%
Return on capital employed 13.9% 10.0% 11.6%
Asset turnover 0.4x 0.5x 0.5x
Cash conversion (OCF / net income) 1.4x 1.2x 1.7x
Stock comp / revenue 2.2% 1.5% 2.6%

Financial Health

11 metrics
MetricMDTBSXEW
Debt / assets 30.2% 26.3% 4.2%
Debt / equity 0.6x 0.5x 0.1x
Net debt / EBITDA 1.2x 2.1x -2.5x
Debt / FCF 2.2x 3.6x 0.4x
Liabilities / assets 45.5% 43.1% 22.5%
Equity / assets 54.5% 56.9% 77.5%
Interest coverage 8.9x 10.5x –
Current ratio 2.1x 1.4x 4.6x
Quick ratio 1.3x 0.6x 3.5x
Cash ratio 0.7x 0.1x 2.9x
Altman Z-score 3.32 3.03 14.42

Shareholder Returns

7 metrics
MetricMDTBSXEW
Dividend yield 2.8% – –
Net buyback yield -2.6% -0.3% 0.9%
Shareholder yield 0.1% -0.3% 0.9%
Payout ratio (earnings) 41.4% – –
Payout ratio (FCF) 28.7% – –
Dividend growth (1Y) 0.7% – –
Dividend CAGR (3Y) 0.7% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMDTBSXEW
Forward P/E 18.5xFY2026 14.5xFY2026 37.6xFY2026
EPS, next fiscal year $5.57FY2026 $3.06FY2026 $2.85FY2026
EPS growth, next FY +0.7%FY2026 0.0%FY2026 +11.3%FY2026
EPS growth, the year after +7.4% +8.2% +12.6%
Revenue, next fiscal year $39.92BFY2026 $20.48BFY2026 $7.28BFY2026
Revenue growth, next FY +9.8%FY2026 +2.1%FY2026 +19.9%FY2026
Revenue growth, the year after -4.7% -4.0% -2.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMDTBSXEW
Held by institutions 85.1% 90.5% 90.6%
Institutions holding 2,128 1,484 1,326
Change in shares held, QoQ -0.2% -0.7% +20.4%
Institutions buying 1,015 738 641
Institutions selling 915 612 456
Buyers to sellers 1.11 1.21 1.41

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MDTBSXEW
MDT 1.00 0.48 0.36
BSX 0.48 1.00 0.29
EW 0.36 0.29 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MDT, BSX and EW?

Medtronic (MDT) is the largest by market capitalisation: Medtronic (MDT) $132.09B, Boston Scientific (BSX) $63.94B, Edwards Lifesciences (EW) $61.62B.

Which stock is cheaper, MDT, BSX and EW?

Medtronic (MDT) trades on the lowest price-to-earnings ratio (Medtronic (MDT) 15.1x, Boston Scientific (BSX) 18.3x, Edwards Lifesciences (EW) 60.7x). On next year's consensus earnings, Boston Scientific (BSX) is cheapest (Medtronic (MDT) 18.5x, Boston Scientific (BSX) 14.5x, Edwards Lifesciences (EW) 37.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Medtronic (MDT) +12.8%, Boston Scientific (BSX) +8.9%, Edwards Lifesciences (EW) +13.4%.

Which company is more profitable?

Medtronic (MDT) has the highest net margin (Medtronic (MDT) 23.6%, Boston Scientific (BSX) 16.6%, Edwards Lifesciences (EW) 15.2%). On return on invested capital, Medtronic (MDT) leads (Medtronic (MDT) 11.7%, Boston Scientific (BSX) 9.9%, Edwards Lifesciences (EW) 8.7%).

Which stock has performed better?

Over the past year Edwards Lifesciences (EW) returned the most: Medtronic (MDT) +7.0%, Boston Scientific (BSX) -57.8%, Edwards Lifesciences (EW) +24.5%. Over five years, Boston Scientific (BSX) compounded fastest (Medtronic (MDT) -2.9%/yr, Boston Scientific (BSX) +1.1%/yr, Edwards Lifesciences (EW) -1.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Medtronic (MDT) 0.03%, Boston Scientific (BSX) 0.00%, Edwards Lifesciences (EW) 0.00%. Boston Scientific (BSX) and Edwards Lifesciences (EW) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Edwards Lifesciences (EW) has been the steadiest (Medtronic (MDT) 25.6%, Boston Scientific (BSX) 41.5%, Edwards Lifesciences (EW) 25.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MDT, BSX and EW?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Edwards Lifesciences (EW) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.